Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases. Headquartered in South San Francisco, California, the company leverages a precision immunology approach and genetic data analytics to discover and advance its pipeline. Its lead candidate, ESK-001, is an oral, highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor currently in Phase 3 clinical trials for plaque psoriasis and Phase 2 trials for systemic lupus erythematosus. The company is also developing A-005, a central nervous system-penetrant TYK2 inhibitor aimed at treating neuroinflammatory and neurodegenerative conditions such as multiple sclerosis. Originally incorporated in 2021 and formerly known as Esker Therapeutics, the company rebranded to Alumis in 2022. In May 2025, Alumis completed a merger with ACELYRIN, Inc. to further expand its clinical portfolio and strengthen its balance sheet.
